Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment
Autore:
Gram, IT; Ursin, G; Spicer, DV; Pike, MC;
Indirizzi:
Univ So Calif, Norris Comprehens Canc Ctr, Dept Prevent Med, Keck Sch Med,Los Angeles, CA 90033 USA Univ So Calif Los Angeles CA USA 90033 Sch Med,Los Angeles, CA 90033 USA Univ Tromso, Inst Community Med, Sch Med, N-9037 Tromso, Norway Univ Tromso Tromso Norway N-9037 ity Med, Sch Med, N-9037 Tromso, Norway
Titolo Testata:
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
fascicolo: 11, volume: 10, anno: 2001,
pagine: 1117 - 1120
SICI:
1055-9965(200111)10:11<1117:ROGHAI>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
BREAST-CANCER RISK; PARENCHYMAL PATTERNS; REPLACEMENT THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Pike, MC Univ So Calif, Norris Comprehens Canc Ctr, Dept Prevent Med, KeckSch Med,1441 Eastlake Ave, Los Angeles, CA 90033 USA Univ So Calif 1441 Eastlake Ave Los Angeles CA USA 90033 0033 USA
Citazione:
I.T. Gram et al., "Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment", CANC EPID B, 10(11), 2001, pp. 1117-1120

Abstract

Previously, we described the reduction in mammographic densities that occurred in premenopausal women after 12 months on a hormonal regimen designed to be chemopreventive for breast (and ovarian) cancer consisting of a gonadotropin-releasing hormone agonist (GnRHA) plus low-dose add-back estrogen-progestin. We sought to determine whether the density reduction persisted with continuation of the regimen for 24 months, and, if so, whether the densities would return to baseline after the regimen was discontinued. Twenty-one women, 27-40 years of age with a 5-fold greater than normal risk of breast cancer, were randomly assigned in a 2:1 ratio to the treatment group (14 women) and to a control group (7 women). The percentage of mammographic densities, calculated as the proportion of the breast area on the mammogram containing densities, were assessed blindly using a computer-based threshold method at baseline, after 12 and 24 months of treatment, and at between 6 and 12 months after treatment was stopped. The previously described percentage of mammographic density reductions of 9.7% (P = 0.012) after 12 months of treatment were increased slightly to 11.4% (P = 0.010) after 24 months oftreatment, but the additional change was not statistically significant. Ten of 11 treated women assessed at 24 months had reduced percentages of mammographic densities compared with baseline. Six to 12 months after completion of treatment, the mean percentage of mammographic density in the treated group was no different from that at baseline (mean decline of 2.0%; P = 0.73). The women in the control group had no statistically significant changesin densities over the period of the study. Reductions in mammographic densities engendered by the GnRHA plus a low-dose add-back estrogen-progestin regimen persist as long as the women receive treatment. The densities returnto baseline when the women resume normal menstrual cycles. These results confirm that mammographic densities are influenced by ovarian function. Improved efficacy of mammographic screening is to be expected as long as a woman continues on such a regimen. Whether such a regimen is chemopreventive for breast cancer remains to be established, but the recent report on a randomized trial of use of GnRHA alone in premenopausal breast cancer cases showing a marked reduction in incidence of contralateral disease provides strong support for the hypothesis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 10:21:57